Quantcast

Latest Orphan drugs Stories

2011-02-24 02:00:00

WAYNE, N.J. and EMERYVILLE, Calif., Feb. 24, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer. This...

2011-02-21 06:39:00

BARCELONA, Spain, February 21, 2011 /PRNewswire/ -- ADVANCELL (http://www.advancell.net/), an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia (http://www.cancer.gov/) (CLL) patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of...

2011-02-15 15:00:00

EMERYVILLE, Calif., Feb. 15, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to provide a general business overview, as well as to discuss fourth quarter and full year 2010 financial results, on Wednesday, February 23, 2011, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the fourth quarter and full year ended December 30, 2010 will be released earlier that day....

2011-01-31 15:11:00

EMERYVILLE, Calif., Jan. 31, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced today that the U.S. Food and Drug Administration (FDA) has granted fast track designation for carfilzomib, a next generation proteasome inhibitor for the potential treatment of patients with relapsed and refractory multiple myeloma. The Fast Track designation process was developed by the FDA to facilitate the development, and expedite the review of drugs to treat serious or...

2011-01-24 05:30:00

BETHESDA, Md., Jan. 24, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax® for Glioblastoma multiforme ("GBM") brain cancer. To date, this trial has been conducted at 13 clinical sites across the U.S., with 33 patients already having been enrolled. These...

2011-01-04 15:00:00

EMERYVILLE, Calif., Jan. 4, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the 29th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2011 at 1:00 p.m. Eastern Time (10:00 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar It is recommended that listeners log on 15 minutes early in order to register and download...

2010-12-27 07:02:00

MORRISTOWN, N.J., Dec. 27, 2010 /PRNewswire/ -- Vicus Therapeutics, LLC, today announced the initiation of a Phase 2 trial evaluating VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar® (sorafenib) tablets, as a potential new treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia. The randomized, open label, multi-center Phase 2 study will evaluate whether VT-122 in...

2010-12-16 11:02:00

Drug not shown to be safe and effective in breast cancer patients SILVER SPRING, Md., Dec. 16, 2010 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) The agency is making this recommendation after reviewing the...

2010-12-11 00:30:30

Combination given to AML, MDS patients who have second disease and no options A two-drug combination is safe and active in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome patients who are usually excluded from clinical trials because they have other illnesses or poor performance status - a measure of disease progression - researchers reported this week at the 52nd American Society of Hematology Annual Meeting. "Our findings suggest current eligibility standards that...

2010-12-07 06:30:00

EMERYVILLE, Calif., Dec. 7, 2010 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive complete results from the Phase 2b 003-A1 study of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. Carfilzomib achieved an overall response rate (ORR) (partial response or greater) of 24.1 percent and a median duration of response (DOR) of 8.3 months in patients who entered the study after...


Word of the Day
drawcansir
  • A blustering, bullying fellow; a pot-valiant braggart; a bully.
This word is named for Draw-Can-Sir, a character in George Villiers' 17th century play The Rehearsal.
Related